Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma.
Frédéric IllouzPhilippe ChansonEmmanuel SonnetThierry BrueAmandine FerriereMarie-Laure Raffin SansonMarie-Christine VantyghemGerald RaverotMathilde MunierPatrice RodienClaire BrietPublished in: European journal of endocrinology (2020)
SRL can induce TSH deficiency in patients with central hyperthyroidism due to TSH pituitary adenoma. Thyrotropic function should be assessed before the first three injections of SRL in order to track TSH deficiency and reduce the frequency of injections when control of thyrotoxicosis rather than tumour reduction is the aim of the treatment.